Our findings suggest that the genotyping of NOTCH1, FBXW7, RAS, and PTEN should be considered for risk-directed therapies, alongside the response to induction chemotherapy, in future TPOG ALL protocols. The gene discussed is PTEN; the disease is acute lymphoblastic leukemia.